Array BioPharma (United States)

InstitutionResearch output, impact & collaborations

Array BioPharma (United States) is a research organisation in Boulder, US. OpenAlex records 559 works and 157,532 citations for it. 223 researchers list it as their most recent affiliation.

559

Works

157,532

Citations

223

Researchers

Avg h-index

IDs:ROR OpenAlex

How has Array BioPharma (United States)'s publication output changed over time?

ScholarIQpublication output · 2016–2019

Output declined50% over the shown period — from 2 works in 2016 to 1 in 2019.

2016201720182019

What are the most-cited papers on Array BioPharma (United States)?

ScholarIQmost cited works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara

The Lancet. 20164,795 CitationsOPEN ACCESS

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck

New England Journal of Medicine. 20183,781 CitationsOPEN ACCESS

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer

The Lancet. 20162,812 Citations

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski, Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski

The Lancet Respiratory Medicine. 2019947 Citations

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters, Scott Gettinger, Melissa L. Johnson, Pasi A. Jänne, Marina Chiara Garassino, Daniel C. Christoph, Chee‐Keong Toh, Naiyer A. Rizvi, Jamie E. Chaft, Enric Carcereny, Jyoti D. Patel, Laura Q.M. Chow, Marianna Koczywas, Cheryl Ho, Martin Früh, Michel M. van den Heuvel, J. Rothenstein, Martin Reck, Luis Paz‐Ares, Frances A. Shepherd, Takayasu Kurata, Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, Alan Sandler, Enriqueta Felip

Journal of Clinical Oncology. 2017420 CitationsOPEN ACCESS